Skip to main content
. 2023 Aug 25;18(8):e0290428. doi: 10.1371/journal.pone.0290428

Fig 1. Survival outcomes are improved in canine DLBCL patients receiving chemoimmunotherapy who progress after 90 days.

Fig 1

(A) Kaplan-Meier analysis for progression free survival (PFS) and (B) overall survival time (OST) in dogs who progressed before and after 90 days. Both PFS and OST were statistically significant between the groups (p<0.0001.) Tick marks indicate censored patients.